MedTrace Logo

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

NCT05661552 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-03-13

No results posted yet for this study

Summary

Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI

Conditions

  • Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia

Interventions

DRUG

Evolocumab 140 MG/ML

Randomly assigned Evolocumab + rosuvastatin + ezetimibe versus rosuvastatin + ezetimibe

DRUG

Rosuvastatin 5mg

Rosuvastatin 5mg will be assigned to all participants

DRUG

Ezetimibe 10mg

Ezetimibe 10mg will be assigned to all participants

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    collaborator INDUSTRY

  • Yonsei University

    lead OTHER

Principal Investigators

  • Yongcheol Kim, MD, PhD · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2025-02-05
Completion
2025-02-05

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05661552 on ClinicalTrials.gov